NCT05344209 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05344209
Title	Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer (LUNGVAC)
Acronym	LUNGVAC
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Vestre Viken Hospital Trust
Indications	lung non-small cell carcinoma
Therapies	Atezolizumab Pembrolizumab Cemiplimab Cemiplimab + Sargramostim + UV1 Telomerase peptide vaccine Pembrolizumab + Sargramostim + UV1 Telomerase peptide vaccine Atezolizumab + Sargramostim + UV1 Telomerase peptide vaccine
Age Groups:	senior \| adult
Covered Countries	NOR

NCT05344209
Clinical Trial Detail